Taysha Gene Therapies’ (TSHA) Buy Rating Reiterated at Needham & Company LLC
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a research report issued on Thursday,Benzinga reports. They presently have a $6.00 price objective on the stock. Needham & Company LLC’s target price would indicate a potential upside of 275.00% from […]
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Needham & Company LLC in a research report issued on Thursday,Benzinga reports. They presently have a $6.00 price objective on the stock. Needham & Company LLC’s target price would indicate a potential upside of 275.00% from […]
